• In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on stroke prevention while reducing clinically relevant bleeding, alongside FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urologic procedures.
• The unusual combination of clinically strong WATCHMAN data and a new kidney-stone-focused irrigation platform with intrarenal pressure management arrives just as analysts question the durability of Boston Scientific’s electrophysiology and Watchman growth engines.
• We’ll now examine how the CHAMPION-AF WATCHMAN results could influence Boston Scientific’s investment narrative, especially around growth sustainability and risk.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Boston Scientific Investment Narrative Recap

To own Boston Scientific today, you need to believe it can keep translating specialty cardiology and urology innovation into durable procedure volume and pricing, despite recent competitive and legal headwinds. The CHAMPION-AF WATCHMAN data strengthen the clinical backbone of one of its key growth engines, but the stock’s sharp pullback and a new securities class action keep the near term centered on sentiment risk rather than a clear, single upside catalyst.

Among the recent announcements, the CHAMPION-AF trial results stand out because they go directly to the heart of the current debate: can WATCHMAN support Boston Scientific’s growth ambitions if electrophysiology momentum softens. By showing non-inferior stroke prevention versus NOACs with lower clinically relevant bleeding, the data could reinforce confidence in left atrial appendage closure as a long-term pillar, even as reimbursement and competition remain active swing factors.

Yet, behind the positive trial headlines, investors also need to weigh the emerging class action and what it could imply for...

Boston Scientific’s narrative projects $27.0 billion revenue and $5.2 billion earnings by 2029.

Uncover how Boston Scientific's forecasts yield a $102.00 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community currently see Boston Scientific’s fair value between US$87 and US$102, highlighting a wide band of conviction. Against that backdrop, the dependence on continued WATCHMAN and electrophysiology adoption after CHAMPION-AF is a key issue that could shape how those expectations eventually line up with business performance.

Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $87.28!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• Find 63 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.